LYON, France, Feb. 6, 2012 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), a global leader in therapeutic ultrasound, announced today the installation of a second Sonolith i-move lithotripter in California, with a group of urologists practicing at USC Medical Center in Los Angeles and UC San Diego, and a further installation in its backlog.
Marc Oczachowski, EDAP's Chief Executive Officer, commented, "We have been very active demonstrating our Sonolith i-move to US urologists since it was cleared by the FDA in August 2011. We continue to receive strong and positive feedback and we are now benefiting from our active marketing campaigns with sales. We recently installed our second Sonolith i-move unit in the US with a well-regarded group of urologists practicing in California at USC Medical Center in Los Angeles and UC San Diego. We also recorded a backlog for a third unit in the New York area from one of the largest and strongest partnerships in the region with more
than 300 urologists. We expect delivery and installation of this machine late in the first quarter or early in the second quarter of 2012."
Marc Oczachowski continued, "We are pleased by the strong and positive interest in our modular real-time 3D imaging lithotripter. Our innovative Sonolith device is very well adapted to clinics and partnerships willing to offer their patients with the best-in-class and latest option for the treatment of urinary stones."
Marc Oczachowski concluded, "These sales are the direct result of several months of marketing actions and demonstrations of our unique and exclusive lithotripsy technology. We are continuing our dynamic and aggressive demonstration tours among some of the largest and well respected groups of urologists around the country. We currently have a strong pipeline of projects and are generating leads for the Sonolith i-move that are gradually converting into sales. We expect to continue to expand our lithotripsy activity in the US."
Sonolith i-move is a compact lithotripter with a revolutionary infrared stereo-vision system for real-time, three-dimensional ultrasound localization of urinary stones. With its various modular configurations, Sonolith i-move will replace Sonolith Praktis, an earlier generation lithotripter, and complements the Company's high-end Sonolith I-sys lithotripter, an integration of x-ray and ultrasound localization systems. Sonolith i-move received European (CE) approval in April 2010, Japanese approval in June 2011 and U.S. marketing clearance in August 2011.
About EDAP TMS SA
EDAP TMS SA develops and markets Ablatherm®, the most advanced and clinically proven choice for high-intensity focused ultrasound (HIFU) treatment of localized prostate cancer. HIFU treatment is shown to be a minimally invasive and effective treatment option with a low occurrence of side effects. Ablatherm-HIFU is generally recommended for patients with localized prostate cancer (stages T1-T2) who are not candidates for surgery or who prefer an alternative option, or for patients who failed radiotherapy treatment. Approved in Europe as a treatment for prostate cancer, Ablatherm-HIFU (High Intensity Focused Ultrasound) is currently undergoing evaluation in a multi-center U.S. Phase II/III clinical trial under an Investigational Device Exemption (IDE) granted by the FDA, the ENLIGHT U.S. clinical
study. The Company also is developing this technology for the potential treatment of certain other types of tumors. EDAP TMS SA also produces and commercializes medical equipment (the Sonolith® range) for treatment of urinary tract stones using extra-corporeal shockwave lithotripsy (ESWL). For more information on the Company, please visit http://www.edap-tms.com, and http://www.hifu-planet.com.
CONTACT: Blandine Confort
Investor Relations / Legal Affairs
EDAP TMS SA
+33 4 72 15 31 72
bconfort@edap-tms.com
Investors:
Stephanie Carrington
The Ruth Group
646-536-7017
scarrington@theruthgroup.com
Source:
EDAP TMS SA
News Provided by Acquire Media
